Andrew is an experienced CEO, having previously led IMV inc. (NASDAQ/TSX) a clinical stage biopharmaceutical company in Oncology. Andrew previously acted as the CBO for IMV and was an executive board member through to the sale of IMV in 2023. Prior to IMV, Andrew spent 7 years at Celgene where he led Corporate Development and pipeline strategy for Immunology, as well a Business Development and Strategic Alliances, working deals from discovery through to commercialization. Earlier in Andrew’s career, he spent more than 15 years at Merck, BMS and Schering Plough in Leadership roles across Asia Pacific, Europe and the United States. He has experience and expertise across multiple disease spaces, all major geographies and in end-to-end drug development, including US and global payer and regulatory dynamics. Andrew holds a Master of Science from RMIT University and a Bachelor of Medical Science (honors) from Melbourne University.